Vir Biotechnology Inc (VIR) FinancialsVIRVir Biotechnology Inc

Evaluating the bottom line, Vir Biotechnology, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 30.75%, while the net margin is 33.51%. These profitability ratios, combined with a Return on Equity (ROE) of -26.08%, provide a clear picture of how effectively VIR converts its operational activities into shareholder value.

In the context of the broader market, VIR competes directly with industry leaders such as ADRX and PVLA. With a market capitalization of $1.98B, it holds a significant position in the sector. When comparing efficiency, VIR's gross margin of 100.00% stands against ADRX's N/A and PVLA's N/A. Such benchmarking helps identify whether Vir Biotechnology, Inc. is trading at a premium or discount relative to its financial performance.

The company's gross margin is strong at 100% for Q2 2026, indicating effective cost management despite recent losses. The total revenue for Q2 2026 was approximately $239 million, showing significant growth compared to previous quarters.